Provided by Tiger Trade Technology Pte. Ltd.

AstraZeneca PLC

160.12
+1.510.95%
Post-market: 160.120.00000.00%19:57 EDT
Volume:2.46M
Turnover:393.68M
Market Cap:248.35B
PE:23.97
High:161.29
Open:159.12
Low:158.53
Close:158.61
52wk High:212.71
52wk Low:153.41
Shares:1.55B
Float Shares:1.50B
Volume Ratio:0.95
T/O Rate:0.16%
Dividend:3.17
Dividend Rate:1.98%
EPS(TTM):6.68
EPS(LYR):6.54
ROE:21.96%
ROA:8.21%
PB:4.94
PE(LYR):24.48

Loading ...

AstraZeneca Wins FDA Priority Review for Rare Bone Disease Drug

MT Newswires Live
·
Sep 18

AstraZeneca Advances Thursday, Outperforms Market

Dow Jones
·
Sep 18

AstraZeneca, Daiichi Breast-Cancer Drug Gets Nod in England After U.S. Pharma Deal

Dow Jones
·
Sep 17

AstraZeneca PLC Stock Falls Wednesday, Underperforms Market

Dow Jones
·
Sep 17

The 'CIA' Strategy Beating the Market: How One Top-Performing Money Manager Spots Mispriced Stocks.

Dow Jones
·
Sep 16

AstraZeneca's Long-Term Outlook Could Look Safer After Next Year

Dow Jones
·
Sep 16

AstraZeneca Can Meet 2030 Target Even if Lung-Cancer Trial Fails

Dow Jones
·
Sep 16

UBS Sticks to Their Buy Rating for AstraZeneca (AZN)

TIPRANKS
·
Sep 16

Guardant Health Could Benefit From AstraZeneca Trial Failure, UBS Says

MT Newswires Live
·
Sep 16

AstraZeneca price target lowered to 150 GBp from 160 GBp at Berenberg

TIPRANKS
·
Sep 16

Berenberg Trims Price Target on AstraZeneca to $203 From $214, Keeps Buy Rating

MT Newswires Live
·
Sep 15

AstraZeneca's Portfolio Diversity Bodes Well

Dow Jones
·
Sep 15

AstraZeneca (AZN) was upgraded to a Hold Rating at Deutsche Bank

TIPRANKS
·
Sep 15

Berenberg Bank Remains a Buy on AstraZeneca (AZN)

TIPRANKS
·
Sep 15

RBC Capital Sticks to Their Buy Rating for AstraZeneca (AZN)

TIPRANKS
·
Sep 15

Top Midday Decliners

MT Newswires Live
·
Sep 15

AstraZeneca PLC Stock Rises Monday, Outperforms Market

Dow Jones
·
Sep 15

AstraZeneca Can Overcome Recent Trial Setbacks

Dow Jones
·
Sep 14

Dow Jones Top Company Headlines at 11 am ET: Microsoft Sets Limits for AI Models as Altman Details Control Risks | Dell's ...

Dow Jones
·
Sep 14

AstraZeneca, Daiichi Drug Has Good Lung-Cancer Data, but Competition Awaits

Dow Jones
·
Sep 14